Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial

2006

Safety and Immunogenicity of a Malaria Vaccine in Malian Adults

Sample size: 40 publication 10 minutes Evidence: moderate

Author Information

Author(s): Thera Mahamadou A, Doumbo Ogobara K, Coulibaly Drissa, Diallo Dapa A, Sagara Issaka, Dicko Alassane, Diemert David J, Heppner D. Gray Jr., Stewart V. Ann, Angov Evelina, Soisson Lorraine, Leach Amanda, Tucker Kathryn, Lyke Kirsten E, Plowe Christopher V

Primary Institution: Malaria Research and Training Center, University of Bamako, Bamako, Mali

Hypothesis

The study aims to evaluate the safety, reactogenicity, and immunogenicity of the FMP1/AS02A malaria vaccine in adults exposed to seasonal malaria.

Conclusion

The FMP1/AS02A malaria vaccine was well tolerated and highly immunogenic, eliciting strong immune responses to diverse malaria parasite clones.

Supporting Evidence

Participants receiving the malaria vaccine had more immediate symptoms at the injection site than the control group.
Antibody levels against the MSP-1 protein increased significantly in the malaria vaccine group.
The vaccine induced responses against all tested alleles of MSP-142.
Safety results were consistent with previous trials of the same vaccine.
Two serious adverse events occurred but were not related to the vaccination.
Immunization with the malaria vaccine led to a significant increase in antibody titers.
Participants in the malaria vaccine group had higher antibody responses at all timepoints measured.
The study was conducted in a population exposed to seasonal malaria transmission.

Takeaway

Researchers tested a malaria vaccine on adults in Mali and found it was safe and helped their bodies fight malaria better.

Methodology

A randomized, double-blind, controlled phase I clinical trial was conducted with participants receiving either the malaria vaccine or a control rabies vaccine.